Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Monlunabant (INV-202) in Diabetic Kidney Disease
NCT05514548Phase 2Completed
- Sponsor
- Inversago
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of monlunabant in diabetic kidney disease (DKD) (3 arms), sponsored by Inversago. Primary endpoint: Change in urine albumin to creatinine ratio at 16 weeks. Started Oct 2022; status: completed.
02
Drugs
monlunabant
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05514548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514548.